23Aug/13

Astellas Pharma launches Astagraf XL in US markets – pharmabiz.com

Astellas Pharma launches Astagraf XL in US markets
pharmabiz.com
The recommended starting dose of Astagraf XL with basiliximab induction is 0.15 mg/kg once-daily. The recommended starting dose of Astagraf XL without basiliximab induction is 0.1 mg/kg once-daily (pre-operative) and 0.2 mg/kg once-daily (post
Astellas’ Astagraf XL Launched in U.S. – Analyst BlogNASDAQ
Astellas Pharma launches once-daily oral tacrolimus formulation in USPharmaceutical Business Review

all 5 news articles »

23Aug/13

Bhopal girl lights hope in death, family makes midnight call to donate her eyes – Times of India

Bhopal girl lights hope in death, family makes midnight call to donate her eyes
Times of India
Uncle Hemant Katare said, “Asmi’s father wanted to donate all her organs to help someone in need, but only her eyes could be donated as she was too young.” Katare also described his grand-daughter as a girl brimming with life, very intelligent and

23Aug/13

Astellas' Astagraf XL Launched in U.S. – Analyst Blog – NASDAQ

Astellas’ Astagraf XL Launched in U.S. – Analyst Blog
NASDAQ
Astagraf XL was approved in the U.S. in Jul 2013 for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction. As per Astellas
ASTELLAS PHARMA INC : ASTAGRAF XLTM (tacrolimus extended-release 4-traders (press release)
Astellas Pharma launches once-daily oral tacrolimus formulation in USPharmaceutical Business Review

all 5 news articles »